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A B S T R A C T
We investigated biomarkers and genetic modulators of the cerebral vasculopathy (CV) subphenotype in pediatric
sickle cell anemia (SCA) patients of sub-Saharan African ancestry. We found that one VCAM1 promoter hap-
lotype (haplotype 7) and VCAM1 single nucleotide variant rs1409419_T were associated with stroke events,
stroke risk, as measured by time-averaged mean of maximum velocity in the middle cerebral artery, and with
high serum levels of the hemolysis biomarker lactate dehydrogenase. Furthermore, VCAM-1 ligand coding gene
ITGA4 variants rs113276800_A and rs3770138_T showed a positive association with stroke events. An additional
positive relationship between a genetic variant and stroke risk was observed for ENPP1 rs1044498_A.
Conversely, NOS3 variants were negatively associated with silent cerebral infarct events (VNTR 4b_allele and
haplotype V) and CV globally (haplotype VII). The -alpha3.7kb–thal deletion did not show association with CV.
However, it was associated with higher red blood cell and neutrophil counts, and lower mean corpuscular
volume, mean corpuscular hemoglobin and red cell distribution width.
Our results underline the importance of genetic modulators of the CV sub-phenotype and their potential as
SCA therapeutic targets. We also propose that a biomarker panel comprising biochemical, hematological,
imaging and genetic data would be instrumental for CV prediction, and prevention.
1. Introduction
Sickle cell anemia (SCA), the homozygous form of the c:20A>T
mutation in the beta-globin gene, is the most common and severe
presentation of sickle cell disease (SCD). High birth rates and child
mortality are most frequent in sub-Saharan Africa, however, population
movements are leading to a wider distribution, emphasizing the global
health emergence status of the disease [1–3]. In children, the most
common sub-phenotypes are cerebral vasculopathy (CV), acute chest
syndrome, hyposplenism, renal disease and painful crises. CV is a major
complication and comprises overt stroke, silent cerebral infarcts (SCIs),
transient ischemic attacks and frequently neurocognitive complications
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at a later stage. Children with SCA have a much higher risk of stroke
than the general pediatric population. The prevalence of overt stroke
approaches 11% by age 20 years. On the other hand, SCIs have been
found in up to 37% of children with SCA [4].
The current standard of care for stroke prevention in SCA children is
Transcranial Doppler (TCD) screening – through measurement of time-
averaged mean velocity (TAMMV) in the middle cerebral artery – fol-
lowed by regular blood transfusions therapy and hydroxycarbamide
(HC) treatment. Despite its high sensitivity, TCD still does not allow
identification of all SCA children that will experience a stroke and,
conversely, children with high TAMMV (>200 cm/s) may not develop
stroke [5]. Moreover, blood transfusion/HC therapies are not without
limitations or adverse side effects [6]. On the other hand, although
diagnosis with magnetic resonance imaging, MRI, (or angiography,
MRA) is recommended for early diagnosis of SCIs and recognition of
large vessel stenosis, MRI/MRA are not useful to identify patients at risk
of developing SCIs or large vessel stenosis [7]. A more specific and
sensitive panel of biomarkers for CV prediction and prognosis, that
includes genetic variants with disease modifying effects, is therefore of
the utmost importance.
In previous studies, we identified variants in VCAM1, NOS3 and
HBA with a positive association with chronic hemolysis, a known pa-
thophysiological SCA mechanism [8]. Building on those results we
aimed, in this work, to assess if those variants were also associated with
pediatric CV in a sub-Saharan SCA population. Our candidate gene
approach also focused on the VCAM-1 ligand gene, ITGA4, and for
comparison purposes, we included the three genetic variants (PON1
rs662, ENPP1 rs1044498 and GOLGB1 rs3732410) previously reported
in association with pediatric stroke in SCA patients [7,9,10].
2. Materials and methods
2.1. Ethical statement
Ethical approval for the study was granted by the institutional re-
view boards of Instituto Nacional de Saúde Dr. Ricardo Jorge (INSA)
and of participant hospitals, in line with the principles of the
Declaration of Helsinki. The aim and study procedures were explained
to the children's parents (or legal guardians) and they provided in-
formed written consent prior to their enrolment in this study.
2.2. Study population
This case-control study was performed at INSA in cooperation with
four hospitals in the Greater Lisbon area – Hospital D. Estefânia,
Hospital de Santa Maria, Hospital Fernando Fonseca and Hospital
Garcia de Orta, the four largest centers of that metropolitan area. These
centers combined receive the highest numbers of SCA pediatric patients
in our country. Seventy unrelated pediatric patients (≥3 years old) of
direct sub-Saharan African ancestry diagnosed with SCA were selected.
Exclusion criteria included age<3 years old, non-African ancestry,
previous HC treatment or having received a blood transfusion in the
120 days prior to enrolment.
Data obtained from patients and parents (or legal guardians) in-
terviews, which included demographic characteristics (age, gender,
parents' geographic origin), were collected. Hemoglobin profiles (HbS,
HbF), hematological parameters [RBC, leukocyte, neutrophil and pla-
telet counts, mean corpuscular volume (MCV), mean corpuscular he-
moglobin (MCH), red cell distribution width (RDW)] as well as hemo-
lysis biochemical and hematological biomarkers [serum LDH and total
bilirubin and reticulocyte count] were retrospectively collected from
patients' hospital records. All these parameters were obtained by stan-
dard procedures and HbF levels, in particular, were measured by high-
performance liquid chromatography (HPLC). The data collected for
each parameter were the result of, at least, three different time-point
measurements, performed in steady-state periods, and prior to any
treatment with HC and more than>120 days after receiving a blood
transfusion. The patients were analyzed according to CV outcome, or
stroke risk, in the following groups (i) overt ischemic stroke (≥1 epi-
sode), henceforth designated as “stroke” (n = 62); (ii) “silent cerebral
infarct”(≥1 event), SCI (n = 53); (iii) stroke and/or SCI, as confirmed
by MRI or MRA, (n = 62); or “stroke risk” (n = 60), with risk strati-
fication provided by the TAMMV values, obtained during TCD, as fol-
lows: (a) high risk – TAMMV≥200 cm/s; (b) conditional (or moderate)
risk – 200 cm/s > TAMMV ≥170 cm/s; and (c) low risk –
TAMMV<170 cm/s.
2.3. Genotyping
Genomic DNA was isolated from peripheral blood samples of each
patient using the MagNA Pure LC Instrument (Roche Diagnostics
GmbH, Mannheim, Germany). All samples were anonymized and spe-
cific genotypes could be linked to phenotypes only through the main
study database.
The homozygous status for the SCA mutation in the HBB gene
(c.20A>T) was confirmed by polymerase chain reaction followed by
restriction fragment length analysis (PCR-RFLP) with the endonuclease
Bsu36 I. Beta-globin cluster haplotypes were assigned after examining
six restriction endonucleases sites within the cluster: Xmn I (5′ to
HBG2), Hind III (within the HBG2 and HBG1) Hinc II (within and 3′ to
ψHBB) and Hinf I (3′ to HBB). Aliquots of the amplified products were
digested with the appropriate enzymes under the conditions re-
commended by the manufacturers. Haplotypes were determined by the
presence or absence of cleavage at each site and by analyzing the
compiled pattern through comparison to known patterns [11]. The
-α3.7kb–thal deletion was assessed by gap-PCR [12].
Putative modifier genes were identified through previous studies by
our group [8] and from other published reports based on the influence
on the phenotypes of interest. These candidate genes were used to
identify and genotype SNPs and other variants in patient samples. For
VCAM1, NOS3, PON1, ENPP1 and GOLGB1 genes genotyping was per-
formed using TaqMan-based PCR with commercially available or cus-
tomized primers.
2.3.1. Screening for ITGA4 variants by next-generation sequencing (NGS)
In order to search for variants in the regulatory region of ITGA4
gene, NGS analysis was used on a long PCR fragment (4.1 kb), including
its flanking regions. PCR was performed using the primers FW5’-CAG
AGGCTCATTAGGACCC-3′ and Rv5′-CCTTGCGGTACTATCCAGGC-3′
and the FailSafe enzyme with the PreMix G (Epicentre, Illumina, San
Diego).
The NGS workflow consisted in five steps: PCR product purification
using paramagnetic beads (Agentcourt, Ampure XP); double-stranded
DNA quantification in a Qubit fluorometer; DNA library preparation
using the Nextera XT kit (Illumina, San Diego) following the manu-
facturer's instructions; high throughput sequencing in a MiSeq benchtop
sequencer (Illumina, San Diego); data analyses were performed using
the following tools: Sequencing Analysis Viewer (v1.8.46, Illumina) and
FastQC (v0.11.5, Babraham Bioinformatics,https://www.
bioinformatics.babraham.ac.uk/projects/fastqc/) were used for
quality analysis. The MiSeq® Reporter software package (v2.6.2,
Illumina) was used for read mapping (with Burrows-Wheeler Aligner)
and variant calling and filtering (with Genome Analysis Toolkit). FastQ
screen (v.0.9.3, Babraham Bioinformatics) was used to screen for con-
tamination between samples. Variant Effect Predictor (www.ensembl.
org) was used to annotate variants and Integrative Genomics Viewer
(v.2.3.86) (Broad Institute; [13]) was used for visualization of reads and
variants. Validation of the variants was performed using automated
Sanger sequencing, after amplification with customized primers in the
3130XI Genetic Analyser, (Applied Biosystems). The results were ana-
lyzed using FinchTV v.1.4.0 software (Geospiza, Inc.). The genotyping
results were added to the previously created database.
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2.3.2. Haplotype reconstruction
Haplotype reconstruction was performed using PHASE software
v2.1 developed by Mathew Stephens at Washington University, ac-
cording to the developer's instructions (https://els.comotion.uw.edu/
express_license_technologies/phase). Haplotypes were reconstructed for
genetic variants in NOS3 (rs2070744, intron 4_27 bp VNTR,
rs1799983), in the promoter of VCAM1 (rs1409419, rs3917024,
rs3917025, rs3783598, rs1041163, rs3783599) and for genetic variants
of ITGA4 (rs1375493, rs35723031, rs10562650; rs1839269 and
rs1839268).
2.3.3. In silico analysis
Population allele and genotype frequencies were recorded for each
observed variant using the Ensembl browser (www.ensembl.org). SNPs'
sequences were retrieved using the NCBI SNP search engine (http://
ncbi.nlm.gov/snp).
Transcription factor binding sites (TFBS) analysis was performed for
the variants identified in the regulatory regions, using the MatInspector
tool (Genomatix, Munich, Germany), to evaluate potential effects on
the regulation of gene expression by altering putative TFBS. Only re-
sults above the 0.85 threshold were considered, which corresponds to a
maximum of 15% dissimilarity between the identified sequence and the
consensus sequence. A comparison with previously reported consensus
sequences of TFBS for the VCAM1 [14] and the ITGA4 [15] promoters
was performed. The sequences of the identified variants were not found
to overlap with any of the previously reported TFBS consensus se-
quences. Hence, no strong effects for these genes' expression are to be
expected as a result of the presence of those variants.
2.3.4. Statistical analysis
The analyses were performed using the SPSS software (version 25.0,
IBM Inc., Chicago, USA). For descriptive analysis, continuous variables
were represented as medians and interquartile ranges (IQR). To eval-
uate the Gaussian distribution of variables, Shapiro-Wilk normality
tests where applied. We used the Mann-Whitney U test to compare the
medians of variables. Categorical variables are represented as number,
frequencies and percentages. The chi-square test or the Fisher's exact
test were used to compare categorical variables on bivariate analysis.
Statistical significance was defined as p < 0.05.
The minor allele for each variant was evaluated for potential asso-
ciation with stroke, SCI, cerebral vasculopathy (stroke and SCI com-
bined) or risk (as measured by TCD-TAMMV values), via 2 × 2 phe-
notype × genotype contingency tables. Only polymorphisms with a
minor allele frequency (MAF) > 5% were considered for association
analysis. Phenotypes were classified as follows: (i) “stroke” (at least one
previous overt ischemic stroke event, as confirmed by MRI/MRA) or
“no stroke” (no clinically/imaging identified stroke event); (ii) “SCI” (at
least one event as identified by MRI/MRA) or “no SCI” (no SCI events,
as confirmed by MRI); (iii) “cerebral vasculopathy” (at least one overt
ischemic stroke and/or SCI event) or “no cerebral vasculopathy”; and
(iv) “risk of stroke” (high/moderate: TAMMV ≥ 200 cm/s or
199 ≥ TAMMV ≥ 170 cm/s; low: TAMMV < 170 cm/s).
Each variant was also evaluated for potential association with bio-
chemical and hematological parameters, including hemolysis bio-
markers (LDH, total bilirubin, reticulocyte count).
3. Results
3.1. Population description and genotyping
This study was performed on seventy unrelated SCA patients, (age
range: 3–16 years, 40 males, 30 females), living in Portugal but of direct
sub-Saharan ancestry, with parental geographic origin mainly from
Angola, São Tomé and Príncipe and Cape Verde (Table 1).
A total of seventy-one genetic variants were identified of which
twenty-eight (MAF > 0.05) were used in the association studies –
seven in VCAM1, five in NOS3, three in GOLGB1, one in PON1, one in
ENPP1, one in HBA (-α3.7kb–thal) and ten in ITGA4 (Appendix Table
A.1). We were able to reconstruct 16 haplotypes, and used ten of them
(frequency > 0.05) for statistical analysis. Concerning the HBB gene
cluster haplotypes, only the more frequent genotypes, Bantu/Bantu and
Senegal/Senegal, were used for statistical analysis (frequency > 0.05).
3.2. In silico analysis
In silico analysis of the VCAM1 gene promoter variants was focused
on those with MAF > 0.05, except rs3917025 due to its occurrence in
only one haplotype (Haplotype 3). The rs1041163_C, rs1409419_T and
rs3917025_delCT VCAM1 alleles were classified (according to ClinVar
and Ensembl's VEP and Mat Inspector) as intergenic variants with po-
tential modifying impact, although with no major pathologic effects.
Potential changes resulting from the presence of the rs1041163_C allele
include (i) TFBS alteration for RXRF transcription factor, substituting it
for a PRDF site, and (ii) loss of a FHXB TFBS. The presence of
rs1409419_T would lead to a potential gain of binding sites, in parti-
cular, for EVI1, Oct1 and Barx2. Regarding rs3917025_delCT, a po-
tential gain of a FAST1 (FoxH1) TFBS was indicated.
Table 1






Parental geographic origin n %
Angola 42 60.0
São Tomé and Príncipe Islands 8 11.4




Double origin 6 8.6















High (TAMMV≥200 cm/s) 25 41.7
Moderate (170 cm/s ≤ TAMMV ≤ 200 cm/s) 6 10.0
Low risk (TAMMV<170 cm/s) 29 48.3
Hematological parameters Median IQR
Hb S (%) 79.9 14.5
Hb F (%) 10.7 11.7
Hb (g/dL) 8.0 1.3
RBC (×1012/L) 3.0 0.7
MCV (fL) 81.3 14.3
MCH (pg) 26.9 6.0
Reticulocytes (%) 9.9 6.3
RDW (%) 21.2 4.5
Platelets (×109/L) 404.1 167.7
WBC (×109/L) 12.6 4.8
Neutrophils (×109/L) 5.6 2.65
Biochemical parameters Median IQR
LDH (U/L) 636.3 473.4
Total bilirubin (mg/dL) 2.6 1.9




Compound heterozygous 17 24.2
Atypical 1 1.4
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3.3. Association of biochemical and hematological parameters with cerebral
vasculopathy
We observed significant associations of both stroke and stroke risk
with several biochemical and hematological parameters (Table 2).
Lower HbF percentages and MCH values were positively associated
with stroke, while stroke risk was associated not only to lower HbF
percentage but also to higher levels of coagulation, inflammation and
hemolysis markers (Table 2).
3.4. Association of genetic variants with biochemical and hematological
parameters
Genetic variants analyzed in our study, using the dominant genetic
test model, showed association with both hematological and biochem-
ical parameters, whether individually or as part of specific haplotypes
(Table 3). VCAM1 rs1041163 (CC + TC), VCAM1_haplotype 3, ITGA4
rs113276800 (CA) and ITGA4 rs3770138 (TT + CT) showed an asso-
ciation with lower levels of HbS. Conversely, higher HbF percentages
were observed in association with rs1041163 (CC + TC), VCAM1_ha-
plotype 3 and with Senegal/Senegal haplotype.
Namely, VCAM1 as well as ITGA4 variants, individually or within a
haplotype context, were significantly associated with traditional bio-
markers of disease severity, such as lower HbS percentage and higher
LDH and total bilirubin values.
As for PON1 rs662, the AA and GA genotypes showed a positive
association with high platelets counts characteristic of a pro-coagulant
state. Regarding GOLGB1, no significant association was found between
the presence of rs3742410_C and hematological or biochemical para-
meters. However, we found two other GOLGB1 SNPs while analyzing
rs3732410_C – rs61746571_G and rs33988592_A, a synonymous and a
missense variant, respectively. The rs61746571_G seems to be in
linkage disequilibrium with variant rs3732410_C. On the other hand,
rs33988592 AA and GA genotypes showed an association with lower
values of inflammation markers (Table 3).
Table 2
Association of biochemical and hematological parameters of SCA patients with
stroke and stroke risk.
Parameter (units) n Stroke p
Yes No
Medians (IQR) Medians (IQR)
HbF (%) 64 3.2 (9.3) 11.9 (10.3) 0.018
MCH (pg) 70 21.2 (20.8) 27.4 (6.0) 0.005
Parameter (units) n Stroke risk p
High + moderate Low
Medians (IQR) Medians (IQR)
HbF (%) 64 8.5 (10.2) 12.1 (10.7) 0.043
Platelets (×109/L) 61 442.0 (156.4) 363.2 (124.2) 0.017
Neutrophils (×109/L) 61 6.3 (2.5) 4.9 (2.6) 0.009
LDH (U/L) 65 761.5 (535.7) 510.0 (325.3) < 0.001
Values indicated as medians (interquartile range in brackets); n - number of
patients; HbF - hemoglobin F; MCH - mean corpuscular hemoglobin; LDH -
lactate dehydrogenase.
Table 3
Genetic variants association with the hematological and biochemical para-
meters.





HbS (%; n = 60)
Var No var
VCAM1 rs1041163 T>C 74.5 83.5 0.019
Haplotype 3 C/C/CT/T/C/C 73.7 81.4 0.034
rs33988592 G>A 11.3 13.4 0.030
ITGA4 rs113276800 C>A 69.0 80.4 0.012
rs3770138 C>T 66.1 80.7 0.003
HbF (%; n = 64)
Var No var
VCAM1 rs1041163 T>C 13.0 7.0 0.014
Haplotype 3 C/C/CT/T/C/C 14.5 9.3 0.005
HBB Haplotype Sen/Sen 13.6 9.2 0.038
Hb (g/dL; n = 65)
Var No var
HBB Haplotype Sen/Sen 8.1 7.9 0.022
RBC (×1012/L;
n = 64)
HBA -α3.7kb del αα > -α3.7kb 3.1 2.7 0.008
MCV (fL; n = 69)
NOS3 rs2070744 T>C 87.3 79.9 0.024
Haplotype IV T/4a/G 78.7 83.2 0.032
HBA -α3.7kb del αα > -α3.7kb 75.7 85.7 <0.001
HBB Haplotype Sen/Sen 90.1 80.6 0.039
MCH (pg; n = 70)
Var No var
HBA -α3.7kb del αα > -α3.7kb 25.1 29.0 0.001
RDW (n = 70)
Var No var
NOS3 rs2070744 T>C 19.6 21.6 0.031
Haplotype I C/4a/G 19.6 21.5 0.044




PON1 rs662 G>A 442.0 378.1 0.028
WBC (×109/L;
n = 67)
GOLGB1 rs33988592 G>A 11.3 13.4 0.030




GOLGB1 rs33988592 G>A 5.0 6.2 0.013
HBA -α3.7kb del αα > -α3.7kb 5.7 5.5 0.010
HBB Haplotype Bantu/Bantu 6.2 5.0 0.036
Haplotype Sen/Sen 4.7 6.2 0.014
LDH (U/L; n = 65)
Var No var
VCAM1 rs1409419 C>T 748.0 517.0 <0.001
Haplotype 7 T/C/CT/T/T/C 748.0 517.0 <0.001




VCAM1 rs3783613 G>C 3.2 2.4 0.026
Var – presence of variant allele or haplotype; No var – absence of variant allele
or haplotype; HbS – hemoglobin S; HbF – fetal hemoglobin; Hb – total he-
moglobin; RBC – red blood cells; MCV – mean corpuscular volume; MCH –
mean corpuscular hemoglobin; RDW – red cell distribution width; WBC – white
blood cells; LDH – lactate dehydrogenase; Sen - Senegal.
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3.5. Association of genetic variants with cerebral vasculopathy and cerebral
vasculopathy risk
We found a significant association between the presence of several
of the variants identified and CV/CV risk (Table 4). Namely, VCAM1
rs1409419 (TT + CT), haplotype 7, ITGA4 promoter rs113276800 (CA)
and rs3770138 (TT + CT), showed a positive association with stroke.
ITGA4 variant rs3770138 (TT + CT) was also positively associated with
CV as a whole. Positive associations were also found between high
TAMMV values and VCAM1 rs1409419 (TT + CT), VCAM1 promoter
haplotype 7, and also with the ENPP1 rs1044498_A allele. On the other
hand, NOS3 intron 4 VNTR_4b allele and haplotype V were negatively
associated with SCI, while haplotype VII showed a negative association
with CV overall.
4. Discussion
Our study aimed to assess demographic, clinical, biochemical, he-
matological, genotyping and imaging data to design a potential bio-
marker panel for CV prognosis in children with SCA. With this ap-
proach, we were able to identify statistically significant associations of
biochemical, as well as hematological parameters, with genetic variants
and CV.
In silico analysis of the VCAM1 rs1409419_T allele indicated parti-
cularly interesting potential TFBS gain, namely for EVI1, Oct1 and
Barx2 transcription factors. EVI1 is of special note due to its complexity,
multiple targets and modulation of several numerous processes, in-
cluding cell migration, adhesion and proliferation [16]. It may co-
operate with FOS transcription factor to limit cell adhesion while en-
hancing cell proliferation [16]. Conversely, Oct1 is a TF known to
promote a transcriptional repression/silencing effect, which would
potentially result in VCAM1 down-regulation. On the other hand, a
Barx2 binding site gain, predicted as a result of the rs1409419_T pre-
sence, has been shown to promote murine muscle cell differentiation,
by interacting with muscle regulatory factors, whereas its loss would
lead to decreased adhesion properties [17]. Hence, it is reasonable to
assume that a gain could result in increased adhesion properties. All the
TFs which expression may be affected by the significantly associated
variants are mainly involved in development and in different tissues
following the proposed role of VCAM-1 [18]. It is important to em-
phasize that while we can address the potential effects of the individual
VCAM1 variants' genotypes, the most important modifying role on
disease manifestation would probably arise in the context of the hap-
lotypes that encompass them. The one exception seems to be
rs1409419_T given the overlapping findings observed for this variant
and haplotype 7, which includes it.
Table 4
Genetic variants association with cerebral vasculopathy.
Gene Variant Stroke (n = 62)
Yes No p OR 95% CI
VCAM1 rs1409419_TT+CT 12 23 0.041 4.17 1.04–16.73
rs1409419_CC 3 24
Haplotype 7 12 23 0.041 4.17 1.04–16.73
Haplotype X 3 24
ITGA4 rs113276800_CA 4 3 0.025 7.62 1.39–41.65
rs113276800_CC 7 40
rs3770138_TT+CT 4 4 0.045 5.57 1.12–27.67
rs3770138_CC 7 39
Gene Variant SCI (n = 53)
Yes No p OR 95% CI
NOS3 VNTR_4b 6 42 0.030 0.10 0.01–0.69
VNTR_4a+4c 3 2
Haplotype V 4 36 0.031 0.18 0.04–0.81
Haplotype Y 5 8
Gene Variant CV (n = 62)
Yes No p OR 95% CI
NOS3 Haplotype VII 1 23 0.006 0.08 0.01–0.69
Haplotype Z 13 25
Gene Variant Stroke risk (n = 60)
High + moderate Low p OR 95% CI
VCAM1 rs1409419_TT+CT 23 11 0.009 4.71 1.57–14.13
rs1409419_CC 8 18
Haplotype 7 23 11 0.009 4.71 1.57–14.13
Haplotype X 8 18
NOS3 Haplotype V 18 24 0.050 0.29 0.09–0.96
Haplotype Y 13 5
ENPP1 rs1044498_AA+CA 14 5 0.026 4.03 1.21–13.42
rs1044498_CC 16 23
Haplotype X – presence of any of the other VCAM1 promoter haplotypes studied; Haplotype Y – presence of any of the other NOS3 haplotypes studied; SCI – silent
cerebral infarction; CV – cerebral vasculopathy; 95% CI – 95% confidence interval.
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We found that variants in the gene that encodes the VCAM-1 ligand,
ITGA4, namely rs113276800_A and rs3770138_T were also positively
associated with stroke. Furthermore, the latter was associated with CV
globally. Given its role in WBC, reticulocyte and sickle erythrocyte
adhesion to the activated SCA endothelium, this finding further un-
derlines the role of cell-endothelium adhesion in the severe CV sub-
phenotype. ITGA4 rs113276800 has been previously described in as-
sociation with multiple sclerosis and, as in our case, no AA individuals
were observed [19,20]. This variant is located in the ITGA4 promoter
region near the AP-2 binding sites and the AA genotype may, therefore,
cause a negative expression of the integrin α4 subunit [21]. We also
found that the ITGA4 rs1375493, rs35723031 and rs10562650 variants
behaved similarly in our group of patients, most of whom were het-
erozygous for the three of them simultaneously. Furthermore, the co-
occurrence of minor alleles in haplotype A – which, to our knowledge,
has not been previously described – was associated with lower LDH
values and potentially to a protective effect against hemolysis.
NOS3 (or eNOS) is the major NO-producer enzyme in the cardio-
vascular system, playing a crucial role in vascular tone control, vascular
remodeling and proliferation. Furthermore, in SCA, NO bioavailability
plays a very important modulating role, primarily through scavenging
by cell-free hemoglobin [22]. The rs2070744 variant, located at posi-
tion −786 of the NOS3 gene 5′ flanking region, has been correlated
with cardiovascular disease, namely its C allele, although there is still
debate about how it affects mRNA and protein levels. In our study, we
did not find any association of this variant with CV or stroke risk, which
may be in accordance with previous reports of no significant differences
between CC and TT genotypes effect on NOS3 promoter activity [23].
The fact that the rs2070744_C has different distributions in different
ethnic backgrounds [24] may also be responsible, to some extent, for
these differences, since that allele is more frequent in Caucasians and
our study population is of sub-Saharan origin. However, we observed a
significant association between CC and TC genotypes of this variant and
lower RDW, which has been discussed as a possible biomarker of lower
cerebrovascular disease risk [25]. Lower RDW values (or reduced ani-
socytosis) would potentially act as a protective factor in consonance
with what we observed for NOS3_haplotype V, which includes allele C,
and CV protection. Although rs2070744 has been described in asso-
ciation with cardiovascular disease [26], its role in ischemic stroke has
not been consensual. NOS3_haplotype V also includes intron 4 VNTR_4b
allele, a variant that showed a protective effect against SCI. However,
no relationship with any of the CV presentations studied here was ob-
served. On the other hand, the NOS3 rs1799983_T allele, which leads to
aspartate for glutamate substitution at eNOS position 298, has been
previously reported to be related to deficient eNOS caveolar localiza-
tion and deficient shear stress response leading to reduced enzymatic
activity. This SNP has been found in some populations to be more
prevalent in patients with coronary artery disease, ischemic stroke and
arterial hypertension [27]. However, in our study population, we did
not observe any relationship of rs1799983 TT or GT genotypes with CV,
biochemical or hematological parameters.
Several studies have identified other candidate gene polymorphisms
as potentially affecting the risk of CV. However, the results published so
far have been conflicting. A GWAS study by Flanagan et al. [9], per-
formed in a large cohort of mainly African American SCA pediatric
patients, showed a decreased risk of clinically overt stroke in associa-
tion with GOLGB1 rs3732410_G (Y1212C) and ENPP1 rs1044498_C
(K173Q) mutations, whereas PON1 rs662_C (Q192R) was associated
with increased risk of stroke [9]). In the same study, GOLGB1 Y1212C
was associated with reduced TCD velocities and lower frequencies of
SCIs. Conversely, reports from Martella et al. [7] and Belisário et al.
[10] indicated a link between ENPP1 rs1044498_A and increased stroke
risk as well as high TCD velocities. In our study, the ENPP1
rs1044498_A allele was found in 18% of patients compared to 68.33%
of Martella et al. [7], 26.08% of Belisário et al. [10] and 5.08% of
Flanagan et al. [9], while homozygosity for the GOLGB1 rs3732410_G
allele was not found in our patients as in Flanagan's studies but contrary
to 1.67% in Martella's report. Homozygotes for the PON1 rs662_C allele
occurred in a frequency of 10,3% in our study, whereas Martella et al.
[7] and Flanagan et al. [9] reported 45% and 13.7%, respectively. Of
the three variants, only ENPP1 rs1044498 AA and AC genotypes
showed a positive association with stroke risk. Notably, rs1044498_A is
the minor allele, in our study group, while the variant allele (C) is the
most frequent, which is in line with the reference population (African
Yoruba) and contrary to what is described for the other reference po-
pulations. This may reflect a negative selection for the less advanta-
geous allele - rs1044498_A in these populations. As for the PON1
rs662_C variant, albeit no association with stroke or global CV was
apparent, we observed a positive association with high platelet levels,
indicating a potential impact on hemostasis and inflammation.
The only consensual modifiers of SCD disease severity, so far, have
been the persistence of HbF beyond infancy and the presence of
-α3.7kb–thal deletion. The co-inheritance of -α3.7kb–thal and homo-
zygous HbS mutation has been associated with an overall ameliorating
effect on anemia, particularly a protective effect against stroke in
children [28]. We did not find any direct relationship between the
presence of the -α3.7kb–thal deletion and stroke, although we did find
that patients with α–thal showed a higher RBC count, lower MCV and
MCH, consistent with previous reports [29,30] of ameliorating anemia
factors. Other authors have also reported an absence of association
between -α3.7kb–thal presence and stroke protection [31,32]. Despite
the small sample size in our study, we cannot exclude that population
heterogeneity or other specific population characteristics may con-
tribute for the lack of association observed. Additionally, the un-
expected association with increased neutrophil count might lower the
above mentioned potentially favorable effect by indicating a proin-
flammatory role. The latter was also found in subjects with the Bantu
haplotype while the Senegal haplotype seems to have the opposite ef-
fect, ameliorating inflammation and the hematological indices. Never-
theless, in our study, no HBB cluster haplotypes were found to be as-
sociated with CV.
5. Conclusion
Although the sample size in our study limits extrapolation to the
general SCA pediatric population, our results seem to reinforce the
importance of genetic modulators in the pathophysiology of cerebral
vasculopathy and provide clues for the discovery of novel targets for
SCA therapy. Our findings lead us to suggest that a comprehensive
biomarker panel that includes biochemical, hematological, imaging as
well as genetic data may be very important for CV prediction, and
prevention. Even though the patients we studied are subjected to en-
vironmental, both physical and social, factors different from those to
which the populations their parents originated from have been exposed,
the genetic modifiers described in our study, namely VCAM1 haplotype
7 and rs1409419, may provide further tools for CV prevention in SCA.
Functional studies are of the utmost importance, not only for con-
firmation purposes, but also to assess the mechanisms by which the
phenotype modulation may occur, and the potential use of these var-
iants as novel genetic biomarkers of disease prognosis.
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